Fulgent Genetics, Inc. (FLGT)
USD 18.74
(-3.6%)
USD 18.74
(-3.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -46.55 Million USD | -122.8% |
| 2022 | 221.58 Million USD | -71.82% |
| 2021 | 675.95 Million USD | 133.55% |
| 2020 | 290.15 Million USD | 67893.93% |
| 2019 | 1.67 Million USD | 91.54% |
| 2018 | -2.9 Million USD | -48.74% |
| 2017 | -1.75 Million USD | -469.97% |
| 2016 | 2.08 Million USD | 120.71% |
| 2015 | -4.43 Million USD | -458.82% |
| 2014 | -794 Thousand USD | 0.0% |
| 2001 | 104.33 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -15.13 Million USD | 43.85% |
| 2024 Q2 | -12.75 Million USD | 15.74% |
| 2023 Q1 | -22.85 Million USD | 33.93% |
| 2023 FY | - USD | -122.8% |
| 2023 Q4 | -24.35 Million USD | -467.16% |
| 2023 Q3 | 6.63 Million USD | 149.18% |
| 2023 Q2 | -13.48 Million USD | 41.0% |
| 2022 Q3 | 2.56 Million USD | -90.46% |
| 2022 FY | - USD | -71.82% |
| 2022 Q1 | 202.83 Million USD | 33.65% |
| 2022 Q2 | 26.93 Million USD | -86.72% |
| 2022 Q4 | -34.59 Million USD | -1447.12% |
| 2021 Q4 | 151.77 Million USD | -6.57% |
| 2021 FY | - USD | 133.55% |
| 2021 Q1 | 268.84 Million USD | 19.01% |
| 2021 Q3 | 162.44 Million USD | 64.26% |
| 2021 Q2 | 98.89 Million USD | -63.21% |
| 2020 Q4 | 225.9 Million USD | 255.63% |
| 2020 Q1 | -1.91 Million USD | -367.97% |
| 2020 Q2 | 2.64 Million USD | 237.93% |
| 2020 Q3 | 63.52 Million USD | 2306.17% |
| 2020 FY | - USD | 67893.93% |
| 2019 Q2 | 295 Thousand USD | 116.18% |
| 2019 Q3 | 1.5 Million USD | 411.53% |
| 2019 Q4 | -409 Thousand USD | -127.1% |
| 2019 FY | - USD | 91.54% |
| 2019 Q1 | -1.82 Million USD | -79.43% |
| 2018 Q3 | -846 Thousand USD | 15.48% |
| 2018 Q1 | -2.19 Million USD | -10.36% |
| 2018 FY | - USD | -48.74% |
| 2018 Q4 | -1.01 Million USD | -20.09% |
| 2018 Q2 | -1 Million USD | 54.38% |
| 2017 Q1 | 631 Thousand USD | -49.88% |
| 2017 FY | - USD | -469.97% |
| 2017 Q4 | -1.98 Million USD | -34.23% |
| 2017 Q3 | -1.48 Million USD | -887.33% |
| 2017 Q2 | -150 Thousand USD | -123.77% |
| 2016 Q3 | -611 Thousand USD | -150.16% |
| 2016 Q1 | -416 Thousand USD | 94.19% |
| 2016 Q2 | 1.21 Million USD | 392.79% |
| 2016 Q4 | 1.25 Million USD | 306.06% |
| 2016 FY | - USD | 120.71% |
| 2015 Q1 | 495 Thousand USD | 0.0% |
| 2015 Q2 | 870 Thousand USD | 75.76% |
| 2015 Q4 | -7.15 Million USD | -629.53% |
| 2015 Q3 | 1.35 Million USD | 55.29% |
| 2015 FY | - USD | -458.82% |
| 2014 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 78.206% |
| Prenetics Global Limited | -47.89 Million USD | 2.806% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -2659.455% |
| CareDx, Inc | -89.65 Million USD | 48.078% |
| Exact Sciences Corporation | 41.87 Million USD | 211.166% |
| Exagen Inc. | -19.15 Million USD | -143.053% |
| Inotiv, Inc. | -26.5 Million USD | -75.628% |
| Guardant Health, Inc. | -433.3 Million USD | 89.257% |
| Biodesix, Inc. | -37.1 Million USD | -25.467% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -1773.199% |
| Precipio, Inc. | -4.31 Million USD | -978.092% |
| iSpecimen Inc. | -9.1 Million USD | -411.351% |
| Natera, Inc. | -383.27 Million USD | 87.854% |
| Aspira Women's Health Inc. | -16.49 Million USD | -182.287% |
| Standard BioTools Inc. | -54.45 Million USD | 14.516% |
| 23andMe Holding Co. | -291.87 Million USD | 84.051% |
| Castle Biosciences, Inc. | -45.02 Million USD | -3.394% |
| Personalis, Inc. | -96.8 Million USD | 51.913% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 60.403% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -385.37% |
| OpGen, Inc. | -29.51 Million USD | -57.745% |
| T2 Biosystems, Inc. | -43.87 Million USD | -6.101% |
| Myriad Genetics, Inc. | -67.8 Million USD | 31.339% |
| ICON Public Limited Company | 1.63 Billion USD | 102.853% |
| NeoGenomics, Inc. | -17.6 Million USD | -164.395% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -2659.455% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 103.823% |
| RadNet, Inc. | 292.78 Million USD | 115.9% |
| MDxHealth SA | -30.46 Million USD | -52.79% |
| Psychemedics Corporation | -251 Thousand USD | -18446.614% |
| Illumina, Inc. | -608 Million USD | 92.343% |
| Check-Cap Ltd. | -17.64 Million USD | -163.766% |
| Twist Bioscience Corporation | -176.7 Million USD | 73.656% |
| DarioHealth Corp. | -53.49 Million USD | 12.977% |
| Sera Prognostics, Inc. | -35.28 Million USD | -31.924% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -375.758% |
| OPKO Health, Inc. | -65.51 Million USD | 28.946% |
| Medpace Holdings, Inc. | 363.15 Million USD | 112.819% |
| Neogen Corporation | 182.59 Million USD | 125.494% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -428.357% |
| Prenetics Global Limited | -47.89 Million USD | 2.806% |
| Mainz Biomed B.V. | -25.01 Million USD | -86.125% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -510.174% |
| Trinity Biotech plc | -24.09 Million USD | -93.178% |
| Neuronetics, Inc. | -22.75 Million USD | -104.543% |
| Sotera Health Company | 514.14 Million USD | 109.054% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -510.174% |